Research and clinical trials

The study suggests a possible link between psoriasis, leaky gut, and Crohn’s disease—topics that could help explain why some people with psoriasis report more gut problems. People with psoriasis or IBD may find the...

This study links a specific SERPINB4 gene mutation to impaired intestinal epithelial cell function in twins with Crohn’s disease, which could help explain how rare genetic variants contribute to disease in some patients.

This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.

Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.

Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

A new FDA approval expands treatment options for adults with moderate-to-severe Crohn's disease and means mirikizumab (Omvoh) is now approved for both Crohn's disease and ulcerative colitis. The decision was based on...

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from gastroendonews.com.

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the...

This approval adds a newly authorized biologic option (mirikizumab/Omvoh) for adults with moderate-to-severe Crohn disease, including people who have not done well on steroids, immunomodulators, or prior biologics.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.

This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...

A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...

An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...

An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...

This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...

A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...

A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.

A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...

FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...

People with Crohn’s disease may be affected by the market trends that influence drug availability, costs, and development of new monitoring tools. Emerging monitoring technology could change how flare-ups are detected...

Cure8 found this source from markets.businessinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...

A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...

Patients with Crohn’s disease and other IBD forms may see new research directions aimed at blocking immune cell proliferation by targeting nucleotide metabolism. This is early-stage, preclinical work presented at a...

The story describes a new drug mechanism (dCK inhibition) that reduced inflammation in an IBD mouse model, which could point to a different way to target overactive immune cells in Crohn’s disease. It’s early-stage...

At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...

Genetics can influence Crohn’s disease risk; knowing about risk genes and testing options may help people with a family history understand why disease runs in families and what testing can — and cannot — tell you. The...

This research uses patient-derived “mini-guts” to uncover epigenetic changes that may help explain differences between people with Crohn’s disease and could point to new biological pathways for future therapies.

Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.

This review summarizes who gets Crohn’s disease, likely causes, and modifiable risk factors (notably smoking). That context helps patients and clinicians understand disease origins and the basis for some preventive...

The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...

Skin disease (hidradenitis suppurativa) may be more common in people with IBD—particularly Crohn disease—and could be linked with more severe intestinal complications. Awareness can prompt coordinated care between...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. Open the original article for...

This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...

Some people with Crohn's disease still have symptoms even when inflammation is under control. This study suggests sulfur-producing gut bacteria and their metabolites might explain those lingering symptoms and point to...

The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.

Many people with Crohn’s disease continue to have symptoms even when inflammation is absent. This study suggests the gut microbiome — specifically sulfur-producing bacteria and hydrogen sulfide production — might explain...

Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...

Cure8 found this source from pharmaceutical-technology.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...

This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...

Based on the title and source metadata, this appears to be a basic science related to Research and clinical trials. The original article is from msn.com.